These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27501966)

  • 41. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Volovat C; Gladkov OA; Bondarenko IM; Barash S; Buchner A; Bias P; Adar L; Avisar N
    Clin Breast Cancer; 2014 Apr; 14(2):101-8. PubMed ID: 24485296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
    Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
    J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
    Park KH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Park S; Lee SI; Jung KH; Kim YS; Seo JH
    Support Care Cancer; 2017 Feb; 25(2):505-511. PubMed ID: 27709313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.
    Al-Salama ZT; Keam SJ
    Clin Drug Investig; 2019 Oct; 39(10):1009-1018. PubMed ID: 31489570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.
    Frampton JE; Lee CR; Faulds D
    Drugs; 1994 Nov; 48(5):731-60. PubMed ID: 7530630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
    Shi YK; Feng FY; Sun Y
    Zhonghua Nei Ke Za Zhi; 1994 Nov; 33(11):739-42. PubMed ID: 7541325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Xie J; Cao J; Wang JF; Zhang BH; Zeng XH; Zheng H; Zhang Y; Cai L; Wu YD; Yao Q; Zhao XC; Mao WD; Jiang AM; Chen SS; Yang SE; Wang SS; Wang JH; Pan YY; Ren BY; Chen YJ; Ouyang LZ; Lei KJ; Gao JH; Huang WH; Huang Z; Shou T; He YL; Cheng J; Sun Y; Li WM; Cui SD; Wang X; Rao ZG; Ma H; Liu W; Wu XY; Shen WX; Cao FL; Xiao ZM; Wu B; Tian SY; Meng D; Shen P; Wang BY; Wang Z; Zhang J; Wang L; Hu XC
    Breast Cancer Res Treat; 2018 Apr; 168(2):389-399. PubMed ID: 29230663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
    Ji X; Xu L; Pan P; Xu Z; Wang A; Li Y
    Thorac Cancer; 2022 Jan; 13(1):117-125. PubMed ID: 34791805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
    Petru E; Singer CF; Polterauer S; Galid A; Schauer C; Klocker J; Seifert M; Reinthaller A; Benedicic C; Hubalek M; Hefler L; Marth C; Scholl-Firon T; Bogner G; Zeimet AG
    Wien Med Wochenschr; 2015 Oct; 165(19-20):387-94. PubMed ID: 26471371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.
    Ratti M; Tomasello G
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):15-24. PubMed ID: 25409861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
    Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage.
    Yan B; Zhang W; Lu F; Chen ZL; Han BH; Jiang LY
    Asian Pac J Trop Med; 2013 Nov; 6(11):912-5. PubMed ID: 24083590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study.
    Liu C; Hao Y; Wang L; Meng F; Wen F; Zhong D
    Thorac Cancer; 2021 Apr; 12(8):1154-1161. PubMed ID: 33590721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.
    Johnston E; Crawford J; Blackwell S; Bjurstrom T; Lockbaum P; Roskos L; Yang BB; Gardner S; Miller-Messana MA; Shoemaker D; Garst J; Schwab G
    J Clin Oncol; 2000 Jul; 18(13):2522-8. PubMed ID: 10893282
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
    Riedel RF; Andrews C; Garst J; Dunphy F; Herndon JE; Blackwell S; Barbour S; Crawford J
    J Thorac Oncol; 2007 Jun; 2(6):520-5. PubMed ID: 17545847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.